1. The hypothalamic releasing and inhibiting hormones differ markedly in peptide chain length, a feature relevant to their susceptibility to peptidase degradation and analog design. Which of the following correctly states the structure of gonadotropin-releasing hormone (GnRH)?
A) GnRH is a 41-amino-acid peptide, the longest of the hypothalamic releasing hormones, accounting for its relatively prolonged plasma stability compared with shorter hypothalamic peptides
B) GnRH is a decapeptide (10 amino acids) with a native plasma half-life of only 2 to 4 minutes due to rapid peptidase cleavage, the structural template on which agonist and antagonist analogs are built
C) GnRH is a tripeptide (pyroGlu-His-Pro-NH2), the smallest hypothalamic releasing hormone, which limits the number of positions available for D-amino acid substitution in analog design
D) GnRH is a nonapeptide (9 amino acids) synthesized in the supraoptic nucleus and stored in the posterior pituitary alongside oxytocin and vasopressin before release into the systemic circulation
E) GnRH is a 44-amino-acid peptide with a biologically active N-terminal fragment, structurally homologous to growth hormone-releasing hormone and sharing its Gs-coupled signaling pathway
ANSWER: B
Rationale:
This question asked you to recall the precise structure of GnRH. GnRH is a decapeptide — a 10-amino-acid peptide — synthesized in hypothalamic neurons and released in pulses into the hypophyseal portal circulation. Its native plasma half-life is only 2 to 4 minutes because serum and tissue peptidases rapidly cleave it; this short half-life is precisely why therapeutic GnRH analogs incorporate D-amino acid substitutions (commonly at position 6) and C-terminal amidation to resist degradation. The decapeptide serves as the structural template for both agonist analogs (leuprolide, goserelin, buserelin) and peptide antagonist analogs.
Option A: Option A is incorrect because the 41-amino-acid peptide is corticotropin-releasing hormone (CRH), not GnRH.
Option C: Option C is incorrect because the tripeptide pyroGlu-His-Pro-NH2 is thyrotropin-releasing hormone (TRH), not GnRH.
Option D: Option D is incorrect because the nonapeptides synthesized in the supraoptic and paraventricular nuclei and stored in the posterior pituitary are oxytocin and vasopressin; GnRH is a decapeptide that acts on the anterior pituitary via the portal circulation, not a posterior pituitary nonapeptide.
Option E: Option E is incorrect because the 44-amino-acid peptide with an active N-terminal fragment is growth hormone-releasing hormone (GHRH); GnRH is unrelated to GHRH in length and uses Gq, not Gs, signaling.
2. The hypothalamic releasing hormones signal through G protein-coupled receptors, but they differ in which G protein they engage and therefore in their downstream second messenger pathways. Which of the following correctly describes the thyrotropin-releasing hormone (TRH) receptor and its primary signaling pathway?
A) The TRH receptor is Gs-coupled, activating adenylyl cyclase to raise cyclic AMP and activate protein kinase A, the same pathway used by the corticotropin-releasing hormone type 1 receptor
B) The TRH receptor is Gi-coupled, inhibiting adenylyl cyclase and reducing cyclic AMP, the same inhibitory pathway used by all five somatostatin receptor subtypes
C) The TRH receptor is a ligand-gated calcium channel that permits direct calcium entry into thyrotroph cells upon TRH binding, bypassing G protein involvement entirely
D) The TRH receptor is Gq-coupled, activating phospholipase C beta to generate inositol trisphosphate and diacylglycerol, mobilizing intracellular calcium to trigger TSH secretion — mechanistically identical to GnRH receptor signaling
E) The TRH receptor is a receptor tyrosine kinase that autophosphorylates upon TRH binding and recruits the JAK-STAT cascade to drive TSH subunit gene transcription
ANSWER: D
Rationale:
This question asked you to discriminate the TRH receptor's G protein coupling from the other hypothalamic hormone receptors. The TRH receptor (TRHR) is a Gq-coupled GPCR. Gq activation stimulates phospholipase C beta, which cleaves PIP2 into inositol trisphosphate (IP3) and diacylglycerol (DAG); IP3 mobilizes intracellular calcium and DAG activates protein kinase C, together triggering TSH exocytosis and stimulating TSH subunit gene transcription. This pathway is mechanistically identical to GnRH receptor signaling — both releasing hormones whose receptors are Gq-coupled.
Option A: Option A is incorrect because the Gs-cAMP-PKA pathway is used by the CRH type 1 receptor and the GHRH receptor, not by the TRH receptor; confusing TRH with the Gs-coupled releasing hormones is a common error.
Option B: Option B is incorrect because the Gi-coupled, cAMP-reducing pathway is characteristic of somatostatin receptors (and dopamine D2 receptors), not TRH; TRH is stimulatory via Gq.
Option C: Option C is incorrect because the TRH receptor is not a ligand-gated ion channel; it is a seven-transmembrane GPCR, and calcium elevation occurs through IP3-mediated release from intracellular stores, not direct channel-mediated entry.
Option E: Option E is incorrect because the TRH receptor is not a receptor tyrosine kinase and does not use the JAK-STAT cascade; receptor tyrosine kinases and JAK-STAT signaling are used by growth factor and cytokine receptors, not by hypothalamic peptide GPCRs.
3. Corticotropin-releasing hormone (CRH) acts through two receptor subtypes that differ in their tissue distribution and functional roles. Which of the following correctly distinguishes CRH receptor type 1 (CRH-R1) from CRH receptor type 2 (CRH-R2)?
A) CRH-R1 is the dominant receptor on anterior pituitary corticotroph cells and is the primary mediator of ACTH release, whereas CRH-R2 is expressed more broadly in peripheral tissues including heart, skeletal muscle, and brain, where it modulates stress responses and energy homeostasis
B) CRH-R1 is expressed exclusively in the adrenal cortex where it directly stimulates cortisol synthesis, whereas CRH-R2 is the pituitary receptor responsible for ACTH secretion from corticotroph cells
C) CRH-R1 is Gi-coupled and inhibits ACTH release as a negative feedback brake, whereas CRH-R2 is Gs-coupled and provides the stimulatory drive for ACTH secretion at the pituitary
D) CRH-R1 and CRH-R2 are functionally interchangeable, both expressed equally on corticotroph cells, and pharmacological blockade of either alone fully abolishes the ACTH response to CRH
E) CRH-R1 is a receptor tyrosine kinase mediating chronic trophic effects on corticotroph proliferation, whereas CRH-R2 is the GPCR responsible for acute, minute-to-minute ACTH secretion
ANSWER: A
Rationale:
This question asked you to discriminate the two CRH receptor subtypes by tissue distribution and function. CRH-R1 is the dominant receptor on anterior pituitary corticotroph cells and is the primary driver of ACTH secretion in response to hypothalamic CRH. CRH-R2 has a broader peripheral distribution — including heart, skeletal muscle, and brain — where it modulates stress responses, cardiovascular function, and energy homeostasis, rather than serving as the principal pituitary ACTH-release receptor. Both subtypes are Gs-coupled GPCRs that raise cAMP, but their tissue localization assigns CRH-R1 the pituitary ACTH role.
Option B: Option B is incorrect because CRH-R1 is not expressed exclusively in the adrenal cortex; ACTH (not CRH directly) stimulates adrenal cortisol synthesis via the melanocortin 2 receptor, and CRH-R1 is the pituitary receptor for ACTH release — the option inverts the pituitary assignment.
Option C: Option C is incorrect because both CRH-R1 and CRH-R2 are Gs-coupled and stimulatory; neither is a Gi-coupled inhibitory receptor, and CRH-R1 provides the stimulatory ACTH drive at the pituitary, not an inhibitory brake.
Option D: Option D is incorrect because the two subtypes are not interchangeable or equally expressed on corticotrophs; CRH-R1 predominates at the pituitary, and the two receptors have distinct expression patterns and physiological roles.
Option E: Option E is incorrect because neither CRH receptor is a receptor tyrosine kinase; both are GPCRs, and CRH-R1 mediates the acute ACTH secretory response at the pituitary.
4. Growth hormone-releasing hormone (GHRH) stimulates growth hormone secretion from pituitary somatotroph cells. Which of the following correctly identifies the GHRH receptor type and its signaling pathway?
A) The GHRH receptor is Gq-coupled, activating phospholipase C beta to generate IP3 and DAG and mobilize intracellular calcium, the same pathway used by the GnRH and TRH receptors
B) The GHRH receptor is Gi-coupled, inhibiting adenylyl cyclase and reducing cyclic AMP, opposing the inhibitory action of somatostatin at the somatotroph cell
C) The GHRH receptor is Gs-coupled, activating adenylyl cyclase to raise intracellular cyclic AMP and activate protein kinase A, which stimulates both growth hormone gene transcription and growth hormone exocytosis
D) The GHRH receptor is a ligand-gated sodium channel that depolarizes somatotroph cells directly, triggering voltage-dependent calcium entry and growth hormone release independent of any second messenger
E) The GHRH receptor is a nuclear receptor that, upon binding GHRH, translocates to the nucleus to directly activate growth hormone gene transcription over a timescale of hours
ANSWER: C
Rationale:
This question asked you to identify the GHRH receptor type and its signaling pathway. The GHRH receptor is a Gs-coupled GPCR on pituitary somatotroph cells. Gs activates adenylyl cyclase, raising intracellular cAMP and activating protein kinase A (PKA); PKA stimulates both growth hormone gene transcription and GH exocytosis. This Gs-cAMP-PKA mechanism is shared with the CRH type 1 receptor and stands in contrast to the Gq pathway used by GnRH and TRH receptors and the Gi pathway used by somatostatin receptors. Somatostatin opposes GHRH at the somatotroph by its Gi-coupled reduction of cAMP, establishing the push-pull control of GH secretion.
Option A: Option A is incorrect because the Gq-PLC-IP3-DAG pathway is used by the GnRH and TRH receptors, not the GHRH receptor, which is Gs-coupled.
Option B: Option B is incorrect because the GHRH receptor is Gs-coupled and stimulatory (raising cAMP), not Gi-coupled and inhibitory; the Gi-coupled cAMP-lowering receptor at the somatotroph is the somatostatin receptor, which opposes GHRH.
Option D: Option D is incorrect because the GHRH receptor is not a ligand-gated ion channel; it is a GPCR that signals through cAMP, not through direct channel-mediated depolarization.
Option E: Option E is incorrect because the GHRH receptor is a membrane-bound GPCR, not a nuclear receptor; peptide hormones such as GHRH act at cell-surface receptors and signal through second messengers, whereas nuclear receptors bind lipophilic ligands such as steroids and thyroid hormone.
5. Somatostatin exerts its inhibitory effects through a family of five receptor subtypes. Which of the following correctly describes the G protein coupling shared by the somatostatin receptor subtypes and the resulting effect on intracellular signaling?
A) The five somatostatin receptor subtypes are each Gs-coupled, raising cyclic AMP, which is the basis for their stimulation of hormone secretion across endocrine tissues
B) The somatostatin receptor subtypes are Gq-coupled, mobilizing intracellular calcium through phospholipase C beta to promote exocytosis of pituitary and pancreatic hormones
C) Somatostatin receptor subtypes 1 through 3 are Gi-coupled while subtypes 4 and 5 are Gs-coupled, producing opposing effects depending on which subtype predominates in a given tissue
D) The somatostatin receptors are ligand-gated potassium channels that hyperpolarize cells directly upon somatostatin binding, with no associated G protein
E) All five somatostatin receptor subtypes (SSTR1 through SSTR5) are Gi-coupled; Gi activation inhibits adenylyl cyclase and reduces cyclic AMP, and additionally these receptors open inwardly rectifying potassium channels and inhibit voltage-gated calcium channels, collectively suppressing hormone secretion
ANSWER: E
Rationale:
This question asked you to recall the uniform G protein coupling of the somatostatin receptor family. All five somatostatin receptor subtypes (SSTR1 through SSTR5) are Gi-coupled GPCRs. Gi activation inhibits adenylyl cyclase, reducing intracellular cAMP. In addition to lowering cAMP, somatostatin receptor activation opens inwardly rectifying potassium channels (hyperpolarizing the cell) and inhibits voltage-gated calcium channels, and these combined membrane effects suppress hormone secretion across the pituitary (GH suppression), pancreas (insulin and glucagon suppression), and gastrointestinal tract. This uniform inhibitory coupling is why somatostatin and its analogs act as broad secretory inhibitors.
Option A: Option A is incorrect because the somatostatin receptors are Gi-coupled and inhibitory, not Gs-coupled and stimulatory; raising cAMP would oppose somatostatin's known suppressive actions.
Option B: Option B is incorrect because the somatostatin receptors are not Gq-coupled; the Gq-PLC-calcium pathway promotes secretion (as at GnRH and TRH receptors), which is the opposite of somatostatin's inhibitory function.
Option C: Option C is incorrect because the subtypes are not split between Gi and Gs coupling; all five are uniformly Gi-coupled, and there is no Gs-coupled somatostatin receptor subtype.
Option D: Option D is incorrect because the somatostatin receptors are GPCRs, not ligand-gated ion channels; although they do modulate potassium and calcium channels, they do so indirectly through G protein signaling, not by being channels themselves.
6. The somatostatin analogs differ in their somatostatin receptor subtype selectivity, which determines their clinical applications. Which of the following correctly distinguishes the receptor selectivity of octreotide and lanreotide from that of pasireotide?
A) Octreotide and lanreotide are pan-receptor agonists with high affinity for all five SSTR subtypes, while pasireotide is selective for SSTR2 and SSTR5 only, making pasireotide the more narrowly targeted agent
B) Octreotide and lanreotide are selective for somatostatin receptor subtypes 2 and 5 (SSTR2/SSTR5), while pasireotide is a pan-receptor agonist with high affinity for SSTR1, SSTR2, SSTR3, and SSTR5, broadening its activity to tumors with low SSTR2 expression
C) Octreotide is selective for SSTR1 and SSTR4, lanreotide is selective for SSTR3, and pasireotide is selective for SSTR2 alone, so the three agents have entirely non-overlapping receptor profiles
D) Octreotide, lanreotide, and pasireotide all share an identical SSTR2-only selectivity profile, and differ exclusively in plasma half-life rather than receptor affinity
E) Octreotide and lanreotide are SSTR antagonists that block somatostatin binding, while pasireotide is the only somatostatin analog that acts as a true receptor agonist
ANSWER: B
Rationale:
This question asked you to discriminate the receptor selectivity profiles of the somatostatin analogs. Octreotide and lanreotide are SSTR2/SSTR5-selective agonists; because SSTR2 predominates on most GH-secreting pituitary adenomas, these agents are effective in the majority of acromegaly patients. Pasireotide is a pan-receptor agonist with high affinity for SSTR1, SSTR2, SSTR3, and SSTR5; this broader profile gives it efficacy in tumors with low SSTR2 but high SSTR5 expression and in Cushing disease (where corticotrophs express SSTR5 more than SSTR2), at the cost of a substantially higher rate of hyperglycemia from potent SSTR5-mediated insulin suppression.
Option A: Option A is incorrect because it inverts the profiles — octreotide and lanreotide are the SSTR2/SSTR5-selective agents, not pan-receptor agonists, and pasireotide is the pan-receptor agent, not the narrowly targeted one.
Option C: Option C is incorrect because the three agents do not have entirely non-overlapping single-subtype profiles; octreotide and lanreotide share SSTR2/SSTR5 selectivity, and pasireotide overlaps at SSTR2 and SSTR5 while adding SSTR1 and SSTR3.
Option D: Option D is incorrect because the three analogs do not share an identical SSTR2-only profile; their differing receptor selectivity (not merely half-life) is the basis for their distinct clinical niches.
Option E: Option E is incorrect because octreotide, lanreotide, and pasireotide are all somatostatin receptor agonists, not antagonists; they mimic somatostatin to suppress hormone secretion.
7. Oxytocin and vasopressin differ fundamentally from the hypothalamic releasing hormones in their site of synthesis, mode of transport, and route of release. Which of the following correctly describes the synthesis and release of these two posterior pituitary nonapeptides?
A) Oxytocin and vasopressin are synthesized in the arcuate nucleus, released into the hypophyseal portal circulation, and act on anterior pituitary cells to regulate downstream endocrine axes
B) Oxytocin and vasopressin are synthesized by anterior pituitary corticotroph cells, stored in secretory granules, and released into the systemic circulation under hypothalamic releasing-hormone control
C) Oxytocin and vasopressin are nonapeptides synthesized in magnocellular neurons of the supraoptic nucleus (SON) and paraventricular nucleus (PVN), transported axonally to the posterior pituitary, and released directly into the systemic circulation rather than into the portal system
D) Oxytocin and vasopressin are synthesized in the posterior pituitary itself by resident endocrine cells and released locally without any hypothalamic neuronal contribution
E) Oxytocin and vasopressin are synthesized in the median eminence, released into portal blood, and transported to the anterior pituitary where they stimulate prolactin and growth hormone secretion
ANSWER: C
Rationale:
This question asked you to recall the synthesis and release pathway of the posterior pituitary nonapeptides. Oxytocin and vasopressin are nonapeptides (9 amino acids each) synthesized in magnocellular neurons of the supraoptic nucleus (SON) and paraventricular nucleus (PVN) of the hypothalamus. They are transported by axonal flow down the supraopticohypophyseal tract to the posterior pituitary (neurohypophysis), where they are stored in Herring bodies and released directly into the systemic circulation — not into the hypophyseal portal system that serves the anterior pituitary. This direct systemic release distinguishes the posterior pituitary hormones from the hypothalamic releasing hormones, which reach the anterior pituitary via portal blood.
Option A: Option A is incorrect because oxytocin and vasopressin are synthesized in the SON and PVN (not the arcuate nucleus) and are released directly into the systemic circulation, not the portal circulation; the arcuate nucleus is the source of GHRH and tuberoinfundibular dopamine.
Option B: Option B is incorrect because oxytocin and vasopressin are not synthesized by anterior pituitary corticotrophs; they are hypothalamic neuronal products released from the posterior pituitary.
Option D: Option D is incorrect because the posterior pituitary contains axon terminals of hypothalamic neurons, not resident endocrine cells that synthesize these hormones; synthesis occurs in the hypothalamic SON and PVN, and the posterior pituitary serves as a storage and release site.
Option E: Option E is incorrect because oxytocin and vasopressin are not released into portal blood to act on the anterior pituitary; the median eminence and portal blood are the route for hypothalamic releasing hormones acting on the anterior pituitary, whereas the posterior pituitary nonapeptides enter the systemic circulation directly.
8. Vasopressin (antidiuretic hormone, ADH) acts through three receptor subtypes that differ in G protein coupling, tissue location, and physiological effect. Which of the following correctly matches each vasopressin receptor subtype to its coupling and primary action?
A) V1a receptors are Gs-coupled and mediate renal water reabsorption; V1b receptors are Gi-coupled and inhibit ACTH; V2 receptors are Gq-coupled and mediate vasoconstriction
B) V1a, V1b, and V2 receptors are all Gs-coupled and all mediate antidiuresis at different nephron segments, differing only in their anatomical location along the collecting duct
C) V1a receptors mediate antidiuresis in the collecting duct; V1b receptors mediate vascular smooth muscle contraction; V2 receptors mediate pituitary ACTH release — each through Gq coupling
D) V1a receptors are Gq-coupled and mediate vascular smooth muscle contraction and platelet aggregation; V1b (also designated V3) receptors are Gq-coupled and mediate anterior pituitary ACTH release; V2 receptors are Gs-coupled and mediate renal collecting duct aquaporin-2 insertion and antidiuresis
E) All three vasopressin receptor subtypes are ligand-gated calcium channels that produce their distinct effects solely through differences in the magnitude of calcium influx they permit
ANSWER: D
Rationale:
This question asked you to match the three vasopressin receptor subtypes to their coupling and function. V1a receptors are Gq-coupled and mediate vascular smooth muscle contraction (vasoconstriction) and platelet aggregation. V1b receptors (also designated V3 receptors) are Gq-coupled and mediate anterior pituitary corticotroph ACTH release. V2 receptors are Gs-coupled and mediate renal collecting duct aquaporin-2 water channel insertion, producing antidiuresis. This receptor distribution underlies the pharmacology of the class: desmopressin (selective V2 agonist) provides antidiuresis without vasoconstriction; vasopressin (V1a plus V2 agonist) restores vascular tone in septic shock; and the vaptans (tolvaptan, conivaptan) are V2 or non-selective V1/V2 antagonists used for hyponatremia.
Option A: Option A is incorrect because it scrambles the coupling and functions — V2 (not V1a) mediates renal water reabsorption and is Gs-coupled, while V1a is Gq-coupled and mediates vasoconstriction.
Option B: Option B is incorrect because the three subtypes are not all Gs-coupled and do not all mediate antidiuresis; only V2 is Gs-coupled and antidiuretic, while V1a and V1b are Gq-coupled with non-renal actions.
Option C: Option C is incorrect because it misassigns the functions — V2 (not V1a) mediates collecting duct antidiuresis, V1a (not V1b) mediates vascular contraction, and V1b (not V2) mediates pituitary ACTH release; additionally, V2 is Gs-coupled, not Gq-coupled.
Option E: Option E is incorrect because the vasopressin receptors are GPCRs, not ligand-gated calcium channels; their distinct effects arise from differential G protein coupling and tissue distribution, not from graded calcium influx through a channel.
9. Desmopressin (DDAVP) is a synthetic analog of vasopressin used for central diabetes insipidus and certain bleeding disorders. Which of the following correctly describes the pharmacological property that distinguishes desmopressin from native vasopressin?
A) Desmopressin is a synthetic vasopressin analog with selective V2 receptor agonism and negligible vasopressin type 1 (V1) activity, providing antidiuresis (and, via von Willebrand factor release, hemostatic effects) while avoiding the vasoconstriction associated with native vasopressin
B) Desmopressin is a selective V1a receptor agonist that produces potent vasoconstriction, which is the basis for its use in raising blood pressure during central diabetes insipidus
C) Desmopressin is a non-selective V1/V2 receptor antagonist that blocks vasopressin signaling, producing a free water diuresis used to correct hypernatremia
D) Desmopressin is a V1b receptor agonist that stimulates pituitary ACTH release, providing adrenocortical support that indirectly improves renal water handling
E) Desmopressin is identical in receptor selectivity to native vasopressin but differs only in being orally bioavailable, which is its sole pharmacological advantage
ANSWER: A
Rationale:
This question asked you to recall the defining pharmacological property of desmopressin. Desmopressin (DDAVP) is a synthetic vasopressin analog engineered for selective V2 receptor agonism with negligible V1 (V1a) activity. V2 agonism in the renal collecting duct drives aquaporin-2 insertion and antidiuresis, treating central diabetes insipidus, while V2-mediated release of von Willebrand factor and factor VIII provides hemostatic benefit in von Willebrand disease and mild hemophilia A. Because desmopressin lacks meaningful V1a activity, it avoids the vasoconstriction and blood pressure elevation seen with native vasopressin, making it safe for chronic outpatient use.
Option B: Option B is incorrect because desmopressin has negligible V1a activity — it is not a selective V1a agonist and does not produce vasoconstriction; this description is the opposite of its actual receptor selectivity.
Option C: Option C is incorrect because desmopressin is a V2 agonist, not a V1/V2 antagonist; the V2 antagonists are the vaptans (tolvaptan, conivaptan), which produce aquaresis and are used for hyponatremia, not hypernatremia.
Option D: Option D is incorrect because desmopressin does not have meaningful V1b agonist activity and does not act by stimulating ACTH release; its therapeutic action is V2-mediated antidiuresis.
Option E: Option E is incorrect because desmopressin differs from native vasopressin precisely in receptor selectivity (V2-selective with negligible V1 activity), not merely in oral bioavailability; receptor selectivity, not route, is its defining advantage.
10. The vaptans are a class of vasopressin receptor antagonists used in the management of hyponatremia. Which of the following correctly describes the vaptans and their mechanism?
A) The vaptans are V2 receptor agonists that enhance aquaporin-2 insertion to promote water retention, raising serum sodium by hemoconcentration
B) The vaptans are V1a receptor agonists that produce vasoconstriction, indirectly improving renal perfusion and sodium handling in hyponatremic states
C) The vaptans are somatostatin receptor antagonists that block V2-like signaling in the collecting duct through an off-target action at SSTR2
D) The vaptans are oxytocin receptor antagonists repurposed for hyponatremia because of structural similarity between the oxytocin and vasopressin receptors
E) The vaptans (tolvaptan, conivaptan) are vasopressin V2 receptor antagonists — conivaptan additionally blocks V1a — that prevent aquaporin-2-mediated water reabsorption in the renal collecting duct, producing a free water diuresis (aquaresis) that raises serum sodium in syndrome of inappropriate antidiuretic hormone secretion (SIADH)
ANSWER: E
Rationale:
This question asked you to recall the mechanism of the vaptans. The vaptans are vasopressin receptor antagonists: tolvaptan is a selective V2 receptor antagonist, and conivaptan is a non-selective V1a/V2 receptor antagonist. By blocking V2 receptors on renal collecting duct principal cells, the vaptans prevent vasopressin-stimulated aquaporin-2 insertion, reducing water reabsorption and producing a free water diuresis (aquaresis) — the excretion of water without proportional electrolyte loss. This raises serum sodium concentration and is therapeutically useful in euvolemic and hypervolemic hyponatremia, including SIADH.
Option A: Option A is incorrect because the vaptans are V2 antagonists, not agonists; V2 agonism (as with desmopressin) promotes water retention and would worsen, not correct, hyponatremia.
Option B: Option B is incorrect because the vaptans are not V1a agonists; tolvaptan is V2-selective and conivaptan antagonizes both V1a and V2 — neither produces vasoconstriction as a therapeutic mechanism for hyponatremia.
Option C: Option C is incorrect because the vaptans are vasopressin receptor antagonists, not somatostatin receptor antagonists; they act directly at the V2 receptor, not through any SSTR2 off-target effect.
Option D: Option D is incorrect because the vaptans are vasopressin receptor antagonists, not oxytocin receptor antagonists; the oxytocin receptor antagonist atosiban is used as a tocolytic, not for hyponatremia.
11. Prolactin is the only major anterior pituitary hormone under predominantly inhibitory hypothalamic control. Which of the following correctly describes the pathway and receptor responsible for this tonic inhibition?
A) Somatostatin released from the periventricular nucleus binds SSTR5 on lactotroph cells, providing the principal tonic inhibition of prolactin secretion through Gi-mediated cAMP reduction
B) Dopaminergic neurons of the tuberoinfundibular dopaminergic (TIDA) pathway originate in the arcuate nucleus and release dopamine into portal blood, where it binds dopamine type 2 receptors (D2R) on anterior pituitary lactotroph cells, activating Gi to inhibit adenylyl cyclase and suppress prolactin secretion
C) GABAergic neurons project directly from the hypothalamus to the anterior pituitary and synapse on lactotroph cells, hyperpolarizing them through GABA-A chloride channels to inhibit prolactin release
D) Dopamine released from the supraoptic nucleus binds D1 receptors on lactotroph cells, raising cAMP through Gs coupling to suppress prolactin gene transcription
E) Prolactin-inhibiting factor is a distinct peptide hormone, unrelated to dopamine, released from the paraventricular nucleus to bind a dedicated inhibitory GPCR on lactotroph cells
ANSWER: B
Rationale:
This question asked you to identify the inhibitory pathway and receptor controlling prolactin. Dopamine released by the tuberoinfundibular dopaminergic (TIDA) pathway — neurons originating in the arcuate nucleus and projecting to the median eminence — is the primary physiological inhibitor of prolactin secretion. Dopamine reaches the anterior pituitary through portal blood and binds dopamine type 2 receptors (D2R) on lactotroph cells; D2R is Gi-coupled, so its activation inhibits adenylyl cyclase, lowers cAMP, and suppresses both prolactin gene transcription and secretion. This dopamine-D2R inhibitory tone explains why D2R-antagonist drugs (antipsychotics, metoclopramide) elevate prolactin as a class effect.
Option A: Option A is incorrect because somatostatin is not the principal tonic inhibitor of prolactin; its main pituitary target is the somatotroph (GH suppression), and dopamine, not somatostatin, holds the prolactin-inhibiting role.
Option C: Option C is incorrect because the anterior pituitary is regulated humorally via portal blood, not by direct synaptic GABAergic innervation; hypothalamic control of the anterior pituitary is hormonal, not synaptic.
Option D: Option D is incorrect because the relevant dopaminergic neurons arise from the arcuate nucleus (not the supraoptic nucleus, which makes oxytocin and vasopressin), and prolactin inhibition is mediated by Gi-coupled D2 receptors, not Gs-coupled D1 receptors.
Option E: Option E is incorrect because the dominant prolactin-inhibiting factor is dopamine itself, not a distinct unrelated peptide; dopamine functions as the physiological prolactin-inhibiting factor in this context.
12. Several drugs act at the oxytocin receptor (OTR), some as agonists and one as an antagonist. Which of the following correctly characterizes atosiban and distinguishes it from carbetocin?
A) Atosiban is a long-acting oxytocin receptor agonist used to augment labor, while carbetocin is an oxytocin receptor antagonist used as a tocolytic to suppress preterm labor
B) Atosiban and carbetocin are both oxytocin receptor antagonists; they differ only in duration of action, with carbetocin being the longer-acting tocolytic
C) Atosiban is an oxytocin receptor (OTR) antagonist used as a tocolytic to suppress preterm uterine contractions, whereas carbetocin is a long-acting oxytocin receptor agonist (half-life roughly 40 minutes) used to promote uterine contraction
D) Atosiban is a vasopressin V1a receptor agonist that incidentally suppresses uterine contraction, while carbetocin is a selective V2 agonist used to control postpartum hemorrhage
E) Atosiban and carbetocin are both oxytocin receptor agonists used interchangeably for labor induction, differing only in their route of administration
ANSWER: C
Rationale:
This question asked you to distinguish atosiban from carbetocin at the oxytocin receptor. Atosiban is an oxytocin receptor (OTR) antagonist used as a tocolytic — it suppresses uterine contractions in preterm labor (used in Europe for this indication). Carbetocin is a long-acting oxytocin receptor agonist with a plasma half-life of roughly 40 minutes (compared with 3 to 5 minutes for native oxytocin) used to promote uterine contraction, particularly to prevent and control postpartum hemorrhage. The contrast — antagonist tocolytic versus long-acting agonist uterotonic — is the key discrimination.
Option A: Option A is incorrect because it reverses the two drugs: atosiban is the antagonist tocolytic, and carbetocin is the agonist uterotonic, not the other way around.
Option B: Option B is incorrect because carbetocin is an OTR agonist, not an antagonist; only atosiban is the antagonist, so they are not both antagonists.
Option D: Option D is incorrect because atosiban acts at the oxytocin receptor (with some V1a antagonist activity), not as a V1a agonist, and carbetocin is an oxytocin receptor agonist, not a V2 agonist.
Option E: Option E is incorrect because atosiban and carbetocin are not both agonists used interchangeably; atosiban is an antagonist tocolytic and carbetocin is an agonist uterotonic with opposite clinical purposes.
13. Peptide analog design uses specific structural modifications to extend plasma half-life by resisting peptidase degradation. Which of the following correctly describes the mechanism by which D-amino acid substitution and C-terminal amidation extend the half-life of GnRH analogs?
A) D-amino acid substitution adds a polyethylene glycol chain that increases molecular size above the renal filtration threshold, while C-terminal amidation adds a lipid anchor that promotes albumin binding
B) D-amino acid substitution converts the peptide into a non-peptide small molecule resistant to all enzymatic attack, while C-terminal amidation creates a covalent disulfide bridge that locks the molecule into a protease-resistant conformation
C) Both modifications work by encapsulating the peptide in a biodegradable polymer that shields it from plasma enzymes, releasing intact peptide slowly over weeks
D) D-amino acid substitution at a peptidase-susceptible cleavage site (commonly position 6 of GnRH) prevents enzymatic recognition because peptidases are stereospecific for L-amino acids, while C-terminal amidation replaces the free carboxyl terminus with an amide group that retards carboxypeptidase attack
E) D-amino acid substitution increases receptor affinity so the peptide remains bound longer, and C-terminal amidation increases oral bioavailability by enhancing intestinal absorption, neither of which affects enzymatic stability
ANSWER: D
Rationale:
This question asked you to recall the molecular mechanisms of two half-life-extension strategies. Peptidases are stereospecific — they recognize and cleave peptide bonds involving L-amino acids. Substituting a D-amino acid at a peptidase-susceptible cleavage site (commonly position 6 of the GnRH decapeptide) creates a stereochemical mismatch that prevents enzymatic recognition and blocks cleavage at that position, markedly extending plasma half-life. C-terminal amidation replaces the free carboxyl terminus with an amide group; because carboxypeptidases attack free C-terminal carboxyl groups, amidation retards carboxypeptidase degradation. Together these modifications convert a peptide with a 2-to-4-minute half-life into an analog stable for hours.
Option A: Option A is incorrect because D-amino acid substitution does not add a PEG chain (PEGylation is a separate strategy), and C-terminal amidation does not add a lipid anchor; these descriptions confuse distinct modification approaches.
Option B: Option B is incorrect because D-amino acid substitution does not convert the peptide into a non-peptide small molecule — the molecule remains a peptide — and C-terminal amidation does not create a disulfide bridge.
Option C: Option C is incorrect because polymer encapsulation describes PLGA depot formulation technology, not the intrinsic molecular modifications of D-amino acid substitution and amidation.
Option E: Option E is incorrect because the primary purpose of D-amino acid substitution is to resist enzymatic degradation (it does also affect affinity, but the half-life extension is driven by peptidase resistance), and C-terminal amidation acts by blocking carboxypeptidase attack, not by enhancing oral absorption; both modifications fundamentally affect enzymatic stability.
14. Elagolix and relugolix are both oral non-peptide GnRH receptor antagonists, but they differ in the pharmacokinetic pathways that govern their most important drug interactions. Which of the following correctly distinguishes the two agents?
A) Elagolix is metabolized predominantly by cytochrome P450 3A4 (CYP3A4) with a secondary contribution from CYP2C8, making CYP3A4 inducers and inhibitors its principal interaction concern; relugolix is a substrate of the efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), making P-gp inhibitors its principal interaction concern
B) Both elagolix and relugolix are eliminated unchanged by renal excretion, so neither has clinically significant CYP-mediated or transporter-mediated drug interactions
C) Elagolix is a P-glycoprotein substrate while relugolix is metabolized by CYP3A4, the exact reverse of their actual pharmacokinetic profiles
D) Elagolix and relugolix are both peptide analogs cleared by plasma peptidases, so their drug interactions are governed entirely by competition for peptidase activity
E) Both agents are metabolized exclusively by CYP2D6, and neither interacts with efflux transporters or other CYP isoforms
ANSWER: A
Rationale:
This question asked you to discriminate the pharmacokinetic interaction profiles of elagolix and relugolix. Elagolix is metabolized predominantly by CYP3A4 with a secondary contribution from CYP2C8; its key drug interactions therefore involve CYP3A4 inducers (which lower its levels) and inhibitors (which raise its levels). Relugolix is a substrate of the efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP); co-administration with P-gp inhibitors reduces intestinal efflux and markedly increases relugolix exposure, which is its principal interaction concern. Both are non-peptide small molecules designed for oral bioavailability, but their dominant interaction mechanisms differ — hepatic CYP metabolism for elagolix versus intestinal transporter efflux for relugolix.
Option B: Option B is incorrect because neither agent is eliminated primarily unchanged by the kidney; both have clinically significant interactions (CYP3A4 for elagolix, P-gp/BCRP for relugolix).
Option C: Option C is incorrect because it reverses the profiles — elagolix is the CYP3A4-metabolized agent and relugolix is the P-gp/BCRP substrate, not the other way around.
Option D: Option D is incorrect because elagolix and relugolix are non-peptide small molecules, not peptide analogs, and are not cleared by plasma peptidases; their interactions are governed by CYP metabolism and transporter efflux, respectively.
Option E: Option E is incorrect because neither agent is metabolized exclusively by CYP2D6; elagolix uses CYP3A4/CYP2C8, and relugolix's key handling involves P-gp/BCRP efflux transport.
15. GnRH agonists and GnRH antagonists differ in their initial effect on gonadotropin and sex steroid levels at the start of therapy. Which of the following correctly describes this difference and its mechanistic basis?
A) Both GnRH agonists and antagonists produce an initial testosterone surge (flare) followed by suppression, because both classes transiently activate the GnRH receptor before downregulating it
B) GnRH antagonists produce an initial flare while GnRH agonists produce immediate suppression, because antagonists must first occupy and activate the receptor before blocking it
C) Neither GnRH agonists nor antagonists produce any initial change in gonadotropin levels; both classes act only after several weeks of receptor downregulation
D) GnRH agonists produce immediate suppression without a flare, while GnRH antagonists produce an initial flare, the reverse of the conventionally described pattern
E) GnRH agonists produce an initial surge of LH and testosterone (the flare) because they first activate the GnRH receptor before continuous stimulation causes downregulation, whereas GnRH antagonists produce immediate suppression of LH and testosterone without a flare because they competitively block the receptor from the outset
ANSWER: E
Rationale:
This question asked you to discriminate the initial pharmacodynamic effects of GnRH agonists versus antagonists. GnRH agonists (leuprolide, goserelin) first activate the GnRH receptor, producing an initial surge of LH and FSH and a consequent rise in testosterone or estrogen — the "flare" — during the first one to two weeks of therapy. Only with continued continuous receptor occupancy does receptor downregulation set in, after which gonadotropins and sex steroids fall to castrate levels. In prostate cancer, this flare can transiently worsen disease, which is why anti-androgen coverage is given at agonist initiation. GnRH antagonists (degarelix, and the oral agents elagolix, relugolix) competitively block the receptor from the outset, producing immediate suppression of LH, FSH, and sex steroids without any flare.
Option A: Option A is incorrect because only the agonists produce an initial flare; antagonists suppress immediately without a surge, so the two classes do not behave identically.
Option B: Option B is incorrect because it reverses the pattern — agonists produce the flare and antagonists produce immediate suppression, not the other way around; antagonists block rather than activate the receptor.
Option C: Option C is incorrect because both classes do produce early changes — agonists cause an early surge and antagonists cause early suppression; neither requires weeks of downregulation before any effect appears.
Option D: Option D is incorrect because it reverses the conventional and correct pattern: agonists cause the flare, antagonists cause immediate suppression.
16. Somatostatin exists in two biologically active forms derived from a common precursor. Which of the following correctly describes somatostatin-14 and somatostatin-28 and their tissue distribution?
A) Somatostatin-14 and somatostatin-28 are produced from two entirely separate genes on different chromosomes, accounting for their distinct tissue distributions and receptor preferences
B) Somatostatin-14 and somatostatin-28 are both generated by differential cleavage of the same 116-amino-acid preprosomatostatin precursor; somatostatin-14 predominates in hypothalamic neurons projecting to the median eminence, while somatostatin-28 is the dominant form in peripheral tissues including the gastrointestinal tract and pancreas
C) Somatostatin-14 is found only in the pancreas and somatostatin-28 only in the brain, with no overlap, because each form is synthesized exclusively by tissue-specific somatostatin genes
D) Somatostatin-28 is an inactive storage precursor that must be cleaved to somatostatin-14 before any biological activity is possible, so only somatostatin-14 binds somatostatin receptors
E) Somatostatin-14 and somatostatin-28 differ only in their carbohydrate side chains, not in amino acid length, and are distributed identically across all somatostatin-secreting tissues
ANSWER: B
Rationale:
This question asked you to recall the structural relationship and tissue distribution of the two somatostatin forms. Somatostatin-14 and somatostatin-28 are both produced by differential (alternative) cleavage of the same 116-amino-acid preprosomatostatin precursor — they are not products of separate genes. Somatostatin-14 predominates in hypothalamic neurons projecting to the median eminence (the form most relevant to pituitary GH regulation), while somatostatin-28 is the dominant form in peripheral tissues, including the gastrointestinal tract and pancreas. Both forms are rapidly degraded in plasma (half-life 1 to 3 minutes), which drove development of the somatostatin analog class.
Option A: Option A is incorrect because the two forms are not products of separate genes on different chromosomes; both derive from the single preprosomatostatin precursor through differential cleavage.
Option C: Option C is incorrect because the distribution is not absolute and mutually exclusive in that manner — somatostatin-14 predominates centrally and somatostatin-28 peripherally, but both arise from the same precursor rather than from tissue-specific separate genes.
Option D: Option D is incorrect because somatostatin-28 is itself a biologically active form that binds somatostatin receptors; it is not merely an inactive precursor requiring conversion to somatostatin-14 for activity.
Option E: Option E is incorrect because somatostatin-14 and somatostatin-28 differ in amino acid length (14 versus 28 residues), not merely in carbohydrate side chains, and they are not distributed identically across tissues.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.